Haemonetics (HAE) free cash flow

Free cash flow · fiscal 2026
$260.44M

Haemonetics (HAE) generated free cash flow of $260.44M in fiscal 2026 (the year ended March 31, 2026). That is 82.8% higher than the $142.45M of fiscal 2025. Figures as of 18 Nov 2026, 12:01 UTC, from the company's filings with the SEC and Yahoo Finance.

Key facts

Free cash flow, fiscal 2026
$260.44M
Change on fiscal 2025
+82.8%
Growth, 5 years
+29.4% a year
Growth, 10 years
+29.6% a year
Highest on record
$260.44Mfiscal 2026
Lowest on record
$4.96Mfiscal 2015
Fiscal years on record
182009–2026

Figures as of . Older fiscal years come from the company's filings with the SEC, recent ones from Yahoo Finance. Amounts are in USD. Figures, not advice.

Haemonetics free cash flow, in more detail

Over the five fiscal years to 2026 free cash flow grew at a compound 29.4% a year; over ten years the rate was 29.6% a year. Across the 18 fiscal years on record (2009–2026), the highest was $260.44M in fiscal 2026 and the lowest $4.96M in fiscal 2015.

History · 18 fiscal years

Free cash flow by fiscal year

Haemonetics free cash flow, year by year

Haemonetics (HAE) free cash flow by fiscal year
Fiscal yearFree cash flowChangeYear ended
2026$260.44M 82.8% up
2025$142.45M 0.8% down
2024$143.63M 75.7% up
2023$81.73M 7.9% up
2022$75.75M 5.6% up
2021$71.77M 34.4% down
2020$109.46M 171.5% up
2019$40.32M 72.3% down
2018$145.55M 74.1% up
2017$83.60M 329.6% up
2016$19.46M 292.5% up
2015$4.96M 92.5% down
2014$65.88M 187.8% up
2013$22.89M 63.2% down
2012$62.12M 19.1% down
2011$76.79M 3.3% up
2010$74.36M 24.0% up
2009$59.99M—

Change is on the fiscal year before; a dash means that year is not on record or the earlier figure was not positive. A dash anywhere else means the figure was not reported or cannot be computed — it is never filled in.

Method

How it is calculated

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement.

How to read it

It is the cash left for dividends, buybacks, debt repayment and acquisitions; profit that never turns into free cash flow deserves a second look.

Free cash flow at health care companies of similar size

Free cash flow of Haemonetics and comparable companies
CompanyFree cash flowFiscal year
Hims & Hers Health HIMS$57.42M2025
PTC Therapeutics PTCT$411.18M2025
Haemonetics HAE$260.44M2026
Erasca ERAS-$105.08M2025
Concentra Group Holdings Parent CON$197.06M2025
Merit Medical Systems MMSI$212.54M2025

The latest fiscal year on record for each company, in the currency it reports in. Fiscal years end at different times of year.

More on HAE

Haemonetics, figure by figure

Haemonetics (HAE) overview: price, valuation and scorecardAll health care companies by market value

Haemonetics free cash flow: questions and answers

What is Haemonetics's free cash flow?

Haemonetics (HAE) generated free cash flow of $260.44M in fiscal 2026 (the year ended March 31, 2026). That is 82.8% higher than the $142.45M of fiscal 2025.

What is the growth rate of Haemonetics's free cash flow?

Over the five fiscal years to 2026 free cash flow grew at a compound 29.4% a year; over ten years the rate was 29.6% a year.

What are the highest and lowest free cash flow figures on record for Haemonetics?

Across the 18 fiscal years on record (2009–2026), the highest was $260.44M in fiscal 2026 and the lowest $4.96M in fiscal 2015.

How is Haemonetics's free cash flow calculated?

Free cash flow is the cash generated by operations minus capital spending, both taken from the cash-flow statement. For Haemonetics it is on record here for 18 fiscal years, 2009 to 2026.

Fiscal years are named for the calendar year they end in.

Cite this page

Funkfolio, “Haemonetics (HAE) free cash flow”, data as of 18 November 2026. https://funkfolio.com/stock/HAE/free-cash-flow

Underlying data: the company's filings with the SEC and Yahoo Finance.